Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Chukwuemeka Ikpeazu"'
Autor:
Saad A. Khan, MD, Zhuoxin Sun, PhD, Suzanne Dahlberg, PhD, Jyoti Malhotra, MD, Roger Keresztes, MD, Chukwuemeka Ikpeazu, MD, Patrick Ma, MD, Suresh S. Ramalingam, MD, Rathi Pillai, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 5, Pp 100166- (2021)
Introduction: Glycoprotein NMB is a transmembrane protein linked with poor prognosis and is expressed in most squamous lung cancer. Glembatumumab vedotin is an antibody-drug conjugate targeting glycoprotein NMB, administered intravenously every 3 wee
Externí odkaz:
https://doaj.org/article/2314757aa46c4a9e8afca03993ca96d4
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:BPI23-009
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40b738a92200625eb8bcabe6065968f9
https://doi.org/10.6004/jnccn.2022.7130
https://doi.org/10.6004/jnccn.2022.7130
Autor:
Edward S. Kim, Stephen V. Liu, Rebecca Feldman, Matthew J. Oberley, W. Michael Korn, Sachin Gopalkrishna Pai, Hirva Mamdani, Yasmine Baca, Dipesh Uprety, Chukwuemeka Ikpeazu, Vijendra Singh, Ammar Sukari, Chul Kim, Luis E. Raez, Gerold Bepler, Misako Nagasaka, Joanne Xiu, Alexander I. Spira, Hossein Borghaei, Antoinette J. Wozniak
Publikováno v:
Clinical Lung Cancer. 23:52-59
Background HER2 alteration (mutation and/or amplification) is associated with poor survival in NSCLC and can mediate resistance to EGFR tyrosine kinase inhibitors. Methods We retrospectively analyzed de-identified molecular information from 12,946 NS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac2abad234f51266777b1d2227262461
https://doi.org/10.1016/j.cllc.2021.08.012
https://doi.org/10.1016/j.cllc.2021.08.012
Autor:
Arlene A. Forastiere, Harlan A. Pinto, James Ohr, Marshall A. Levine, Shuli Li, Chukwuemeka Ikpeazu, Arnab Chakravarti, Panayiotis Savvides, Nabil F. Saba, Barbara Burtness, Missak Haigentz, Athanassios Argiris, Jill Gilbert, Charles Schneider
Publikováno v:
J Clin Oncol
PURPOSE We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973e58403f6b67c530b10b86c0085bf3
https://doi.org/10.1200/jco.19.00555
https://doi.org/10.1200/jco.19.00555
Autor:
Hira Shaikh, Julie E. McGrath, Brittany Hughes, Joanne Xiu, Pavel Brodskiy, Ammar Sukari, Sourat Darabi, Chukwuemeka Ikpeazu, Chadi Nabhan, Wolfgang Michael Korn, Trisha M. Wise-Draper
Publikováno v:
Cancers; Volume 13; Issue 24; Pages: 6309
Cancers
Cancers, Vol 13, Iss 6309, p 6309 (2021)
Cancers
Cancers, Vol 13, Iss 6309, p 6309 (2021)
Simple Summary The prognosis of recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. However, human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) patients live longer than those
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb0441602e59a1a60b5d1a9ff4fbd8c
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogenic drivers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580d3d8554bc9b006031b5b3be4fa267
http://europepmc.org/articles/PMC8381548
http://europepmc.org/articles/PMC8381548
Autor:
Hira Shaikh, Julie McGrath, Pavel Brodskiy, Joanne Xiu, Chukwuemeka Ikpeazu, Jennifer Leddon, Ammar Sukari, Dan Paul Zandberg, Jim Abraham, Trisha Michel Wise-Draper
Publikováno v:
Journal of Clinical Oncology. 40:e18086-e18086
e18086 Background: BRAF (BRAF mut) is the most common mutation in PTC (45% prevalence). It is associated with a higher clinical stage, tumor recurrence, absence of tumor avidity, and treatment failure. Methods: BRAF WT or BRAF mut (n = 538) PTC tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2276c504fd3c6f458d6b9a1de2700372
https://doi.org/10.1200/jco.2022.40.16_suppl.e18086
https://doi.org/10.1200/jco.2022.40.16_suppl.e18086
Autor:
Z. Sun, Chukwuemeka Ikpeazu, Jyoti Malhotra, Suresh S. Ramalingam, Rathi N. Pillai, Suzanne E. Dahlberg, Patrick Ma, Roger Keresztes, Saad A. Khan
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 5, Pp 100166-(2021)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction Glycoprotein NMB is a transmembrane protein linked with poor prognosis and is expressed in most squamous lung cancer. Glembatumumab vedotin is an antibody-drug conjugate targeting glycoprotein NMB, administered intravenously every 3 week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbfa23179ab2b285e6c8dbd3b7950de
http://www.sciencedirect.com/science/article/pii/S2666364321000254
http://www.sciencedirect.com/science/article/pii/S2666364321000254
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene fusions are oncogenic drive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b44285e8fbea08a948a1657111d74f
https://doi.org/10.1186/s13045-021-01063-9
https://doi.org/10.1186/s13045-021-01063-9
Autor:
Alexander I. Spira, Mark A. Socinski, Hina Khan, Ari M. Vanderwalde, Chul Kim, Joanne Xiu, Hirva Mamdani, Antoinette J. Wozniak, Gilberto Lopes, Yasmine Baca, Stephen V. Liu, Misako Nagasaka, Julia Judd, Chukwuemeka Ikpeazu, Hossein Borghaei, Jorge Nieva, Abdul Rafeh Naqash, Edward S. Kim, Nagla Abdel Karim, Luis E. Raez, W. Michael Korn, Sachin Gopalkrishna Pai
Publikováno v:
Molecular cancer therapeutics. 20(12)
KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a3ab2a19e28f9d931522798d6b5e14
https://pubmed.ncbi.nlm.nih.gov/34518295
https://pubmed.ncbi.nlm.nih.gov/34518295